US · GRCE
Grace Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Princeton, NJ 08540
- Website
- acastipharma.com
Price · as of 2025-03-31
$2.34
Market cap 60.61M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | $0.00 | $1,773.70 | |||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $0.00 | $1,134.00 | |||
| 2015 | $64.50 | $178.10 | |||
| 2016 | $0.00 | $1,131.00 | |||
| 2017 | |||||
| 2018 | $33.12 | ||||
| 2019 | $42.72 | ||||
| 2020 | $36.00 | ||||
| 2021 | $26.40 | $14.55 | $0.00 | ||
| 2022 | $6.00 | $24.53 | |||
| 2023 | $2.94 | ||||
| 2024 | $3.06 | ||||
| 2025 | $2.97 |
AI valuation
Our deep-learning model estimates Grace Therapeutics, Inc.'s (GRCE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $2.34
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GRCE | Grace Therapeutics, Inc. | $2.34 | 60.61M | — | — | — | — | -3.75 | 0.54 | — | -0.83 | — | 2.07 | 0.00% | — | — | -14.91% | -30.04% | -13.17% | 0.00 | — | 11.77 | 11.53 | 1.33 | -5434.00% | — | 2063.00% | -41.52% | -7.72 | -35.82% | 0.00% | 0.00% | 0.00% | -0.83 | -0.92 | — | -0.71 |
| ABVC | ABVC BioPharma, Inc. | $1.31 | 18.98M | +6,706% | +707,778% | — | — | -1.42 | 6.08 | 14.64 | -2.24 | — | 6.08 | 99.85% | -923.34% | -962.12% | -378.31% | -131.15% | -68.64% | 2.61 | -5.70 | 0.33 | 0.32 | -0.54 | -7667.00% | 23431.00% | -5701.00% | -24.25% | -0.28 | -51.48% | 0.00% | 0.00% | 0.10% | -2.07 | -5.38 | 19.10 | -14.83 |
| CALC | CalciMedica, Inc. | $0.52 | 7.44M | — | — | — | — | -1.84 | 1.75 | — | -0.27 | — | 1.75 | 0.00% | — | — | -121.42% | 659.51% | -85.68% | 0.00 | — | 5.34 | 5.07 | 0.33 | -8405.00% | — | -1803.00% | -83.97% | -5.74 | 576.40% | 0.00% | 0.00% | 9.55% | -0.27 | -0.31 | — | -11.56 |
| LTRN | Lantern Pharma Inc. | $2.82 | 31.54M | — | — | — | — | -1.90 | 1.86 | — | -0.70 | 0.00 | 1.86 | 0.00% | — | — | -66.93% | 1620.51% | -60.04% | 0.01 | — | 5.83 | 5.54 | 0.33 | 13125510.00% | — | 2409.00% | -45.25% | -4.11 | 1300.25% | 0.00% | 0.00% | 0.00% | -0.70 | -0.88 | — | -0.66 |
| LVTX | LAVA Therapeutics N.V. | $1.74 | 45.77M | +2,166% | +1,689% | — | — | -1.54 | 1.39 | 3.22 | 1.39 | — | 1.39 | 100.00% | -247.81% | -209.60% | -63.64% | 72.75% | -27.52% | 0.19 | -57.66 | 4.40 | 4.25 | 1.27 | -4013.00% | 7701.00% | -5229.00% | -50.64% | -1.09 | 47.94% | 0.00% | 0.00% | 0.00% | 1.10 | 1.67 | -2.73 | -2.75 |
| OKUR | OnKure Therapeutics, Inc. | $2.71 | 36.72M | — | — | — | — | -1.27 | 0.64 | — | 0.83 | -2.59 | 0.64 | 0.00% | — | — | -5304.43% | 79.46% | -69.93% | 0.01 | -181.29 | 10.73 | 10.52 | 2.12 | 4906.00% | — | 4707.00% | -76.41% | -4.85 | 74.76% | 0.00% | 0.00% | 120.18% | 0.79 | 0.83 | — | 1.25 |
| PDSB | PDS Biotechnology Corpora… | $0.68 | 36.94M | — | — | — | — | -1.19 | 2.36 | — | -0.74 | — | 2.36 | 0.00% | — | — | -166.65% | 954.97% | -71.81% | 1.15 | -7.77 | 2.64 | 2.44 | 0.59 | -2590.00% | — | 423.00% | -78.19% | -2.05 | 943.09% | 0.00% | 0.00% | 0.00% | -0.69 | -0.71 | — | -6.50 |
| RNXT | RenovoRx, Inc. | $0.88 | 32.36M | — | — | — | — | -2.56 | 5.04 | 525.37 | -1.43 | — | 5.04 | 100.00% | -25511.63% | -20497.67% | -1192.69% | 333.89% | -183.93% | 0.06 | — | 4.10 | 3.77 | 0.63 | -2600.00% | — | -1093.00% | -40.45% | -4.78 | 278.10% | 0.00% | 0.00% | 25.24% | -1.43 | -1.72 | 365.46 | -8.52 |
| TVRD | Tvardi Therapeutics, Inc. | $3.99 | 37.43M | +2,851% | +48% | — | +64,129% | -0.32 | -4.89 | 3.15 | -0.46 | -0.01 | -4.89 | 88.62% | -781.57% | -992.95% | 212.65% | 134.22% | -200.11% | -9.68 | -6.58 | 11.03 | 10.67 | -0.10 | 241838.00% | -6596.00% | 19450.00% | -276.02% | -15.34 | 149.93% | 0.00% | 0.00% | 0.00% | -0.52 | -0.47 | 4.06 | -26.80 |
| XLO | Xilio Therapeutics, Inc. | $0.53 | 27.74M | — | — | — | — | -0.84 | 2.76 | 7.67 | -0.03 | — | 2.76 | 100.00% | -954.95% | -918.05% | -214.02% | 466.54% | -88.24% | 0.46 | -605.82 | 2.21 | 2.03 | 0.81 | -6079.00% | — | -7335.00% | -37.86% | -0.67 | 141.80% | 0.00% | 0.00% | 28.58% | -0.02 | -0.08 | 0.24 | -9.18 |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
- CEO
- Prashant Kohli
- Employees
- 4
- Beta
- 0.75
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $2.34) − 1 = — (DCF, example).